Breaking News

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

Ikena Oncology, Inc.

Dr. Marango delivers a long time of valued practical experience in oncology biopharma small business, finance, and company relations & advancement

BOSTON, April 13, 2022 (World NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a qualified oncology business forging new territory in client-directed cancer procedure, right now declared the appointment of Jotin Marango, M.D., Ph.D., to Chief Financial Officer (CFO) and Head of Company Growth. The addition of Dr. Marango, a seasoned pro with just about 15 a long time of sector expertise, comes at a pivotal time as Ikena expands its qualified oncology programs and company growth initiatives.

“Jotin embodies the excellent characteristics we appear for in management at Ikena. He is passionate about advancing treatment plans for clients in want, and his drive is augmented by his accomplished and exclusive qualifications across a number of verticals in the industry,” mentioned Mark Manfredi, Ph.D., Main Executive Officer of Ikena. “As our group grows and our pipeline progresses, we go on to evolve our business and operations methods, supporting and driving execution across our systems. I am hunting ahead to doing work with Jotin on expanding our capabilities, fostering our relationships with the investment community, and looking at the impression of his management throughout the Ikena business.”

Dr. Marango joins Ikena from Aptose Biosciences, in which he served as Senior Vice President, Chief Financial Officer and Chief Organization Officer, foremost all finance and company improvement initiatives for the hematology and oncology-focused company. Prior to becoming a member of Aptose, Dr. Marango worked as an fairness study analyst covering compact and mid-cap biotechnology businesses targeted on hematology, oncology, and exceptional diseases. Dr. Marango also served as Main Working Officer at the Samuel Waxman Cancer Study Foundation, exactly where he oversaw enterprise philanthropy initiatives in therapeutic growth. Through his training and occupation, Dr. Marango has solidified a enthusiasm for working in oncology and facilitating progress for corporations wanting to make a difference in most cancers investigate. Dr. Marango retains a B.A. in Chemistry with Honors from Harvard University and gained his M.D. and Ph.D. from the Mount Sinai Faculty of Drugs of New York University.

“I am thrilled to be becoming a member of Ikena at this sort of an interesting time in the pipeline’s development,” Dr. Marango commented. “As CFO and Head of Corporate Progress, I am searching ahead to doing work with the total team on our mission by creative partnership tactics, robust money operations, and crystal clear and steady conversation with our shareholders and the local community. This is a good possibility to work with a crew that is fully committed to the intention of a entire world in which every single most cancers individual has a treatment.”

About Ikena Oncology
Ikena Oncology™ is focused on building novel therapies focusing on critical signaling pathways that drive the development and distribute of most cancers. The Company’s guide qualified oncology software, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a acknowledged tumor suppressor pathway that also drives resistance to multiple specific therapies. The Company’s ongoing discovery research spans other targets in the Hippo pathway as perfectly as the RAS signaling pathway. More plans concentrating on the tumor microenvironment and immune signaling are in the clinic, which includes IK-175, an aryl hydrocarbon receptor antagonist, which is becoming created in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on addressing genetically defined or biomarker-pushed cancers and producing therapies that can serve specific client populations in need to have of new therapeutic selections. To master far more, check out www.ikenaoncology.com or comply with us on Twitter and LinkedIn.

Forward-Hunting Statements

This press launch consists of forward-hunting statements inside the this means of the Private Securities Litigation Reform Act of 1995, as amended, which includes, without having limitation, statements pertaining to the development of our specific oncology plans our anticipations about the therapeutic advantage of our specific oncology applications expectations with regards to our new government officer our capability to successfully uncover and build product or service candidates the implementation of our small business design, and strategic strategies for our enterprise and product or service candidates. The text “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and related expressions are meant to recognize forward-searching statements, even though not all forward-looking statements incorporate these pinpointing terms. Any forward-wanting statements in this press release are centered on management’s recent anticipations and beliefs and are topic to a variety of threats, uncertainties and significant things that may well induce true activities or results to vary materially from those expressed or implied by any forward-looking statements contained in this push launch, like, without the need of limitation, these dangers and uncertainties linked to the improvement of our focused oncology packages our anticipations relating to the therapeutic benefit of our qualified oncology plans anticipations relating to our new govt officer our ability to efficiently find and create product candidates the implementation of our business enterprise model, and strategic plans for our small business and item candidates, and other elements discussed in the “Risk Factors” segment of Ikena’s Annual Report on Form 10-K for the yr finished December 31, 2021, which is on file with the SEC, as current by any subsequent SEC filings. We caution you not to area undue reliance on any ahead-searching statements, which talk only as of the date they are produced. We disclaim any obligation to publicly update or revise any these types of statements to replicate any modify in anticipations or in events, disorders or conditions on which any this kind of statements may perhaps be based, or that may have an effect on the likelihood that precise results will vary from those people established forth in the forward-looking statements. Any ahead-hunting statements contained in this push launch signify our sights only as of the date hereof and must not be relied on as representing its sights as of any subsequent day. We explicitly disclaim any obligation to update any forward-searching statements.

Media Make contact with:
Gwen Schanker
LifeSci Communications
[email protected]

Investor Get hold of:
Rebecca Cohen
Ikena Oncology
[email protected]